Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Vyndamax approval date?

See the DrugPatentWatch profile for Vyndamax

When was Vyndamax (tafamidis) approved?

Vyndamax (tafamidis) received U.S. approval on April 6, 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). [1]

What product exactly was approved on that date?

The April 6, 2019 approval is for Vyndamax (tafamidis) (the tafamidis product approved for ATTR-CM in the United States). [1]

Where can I verify the approval timeline?

DrugPatentWatch.com lists Vyndamax approval details, including the April 6, 2019 date. [1]

Sources

  1. DrugPatentWatch.com – Vyndamax (tafamidis) approval date


Other Questions About Vyndamax :

Vyndamax generic? How much does vyndamax cost? Vyndamax patent? Vyndamax patent expiration? Vyndamax 61 mg price? When does vyndamax go generic? Vyndamax loe?